<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485546</url>
  </required_header>
  <id_info>
    <org_study_id>NGF0120</org_study_id>
    <nct_id>NCT04485546</nct_id>
  </id_info>
  <brief_title>Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis</brief_title>
  <acronym>DEFENDO</acronym>
  <official_title>An 8-week, Multicenter, Open Label, Prospective Study With 24 Weeks of Follow-up to Evaluate Safety and Efficacy of OXERVATE™ 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis (NK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé Farmaceutici S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dompé US</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dompé Farmaceutici S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL)
      cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal epithelial healing</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage of patients who experience corneal epithelial healing assessed via fluorescein corneal staining</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Neurotrophic Keratitis</condition>
  <arm_group>
    <arm_group_label>OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cenegermin-bkbj</intervention_name>
    <description>Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks</description>
    <arm_group_label>OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj</arm_group_label>
    <other_name>OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥ 18 years.

          2. Patients with Stage 1 NK defined by the Mackie criteria

        Exclusion Criteria:

          1. Evidence of an active ocular infection (bacterial, viral, protozoal) in either eye.

          2. Have current or history of conditions that may confound the study data including but
             not limited to Ocular Cicatricial Pemphigoid (OCP), Graft Versus Host Disease (GVHD),
             neuromyelitis optica, uncontrolled dry eye, and Steven Johnson's syndrome.

          3. History of severe systemic allergy or severe ocular allergy (including seasonal
             conjunctivitis expected during the subject's participation in the trial) or chronic
             conjunctivitis and/or keratitis other than dry eye disease.

          4. Patients with severe vision loss with no potential for visual improvement in the study
             eye, in the opinion of the investigator, or if the subject is deemed legally blind.

          5. Ocular surgery or elective ocular surgery expected during participation in the trial.

          6. Patients with eyelid abnormality that may alter eyelid function including but not
             limited to Blepharospasm, Cerebrovascular accident, entropion, ectropion, floppy lid
             syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Mantelli, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Domp Farmaceutici SpA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgea Pasedis, PharmD Head of Medical Affairs, Dompé US</last_name>
    <phone>1-833-366-7387</phone>
    <email>georgea.pasedis@dompe.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bianca Baker, PhD Assoc. Director, Clinical and Medical Affairs, Dompé US</last_name>
    <phone>1-833-366-7387</phone>
    <email>bianca.baker@dompe.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edgewood</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M. Understanding the Pathogenesis of Neurotrophic Keratitis: The Role of Corneal Nerves. J Cell Physiol. 2017 Apr;232(4):717-724. doi: 10.1002/jcp.25623. Epub 2016 Oct 17. Review.</citation>
    <PMID>27683068</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage 1 Neurotrophic Keratitis</keyword>
  <keyword>Corneal Disease</keyword>
  <keyword>Ocular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

